Study of an experimental vaccine plus pembrolizumab for melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests an experimental personalized cancer vaccine (V940) combined with pembrolizumab (Keytruda) in people with advanced melanoma that cannot be removed by surgery. The goal is to see if this combination helps the immune system fight the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced melanoma (stage III or IV) that cannot be surgically removed, confirmed by biopsy.
- You have not had treatment for advanced melanoma, unless you had prior therapy after surgery that kept you cancer-free for at least 12 months.
- You have at least one tumor that can be measured on a CT scan or MRI.
- You are able to provide a tumor sample (preferably from a metastatic site) for genetic testing.
- You do not have melanoma in the eye or on mucous membranes.
- You have not received certain prior immunotherapies (like PD-1 or CTLA-4 blockers) for advanced melanoma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new approach for advanced melanoma that is not responding to standard immunotherapy (like pembrolizumab). It combines a targeted injection directly into the tumor (L19IL2, L19TNF, or both) with pembrolizumab. The goal is to see if this combination can shrink tumors and help the immune system fight the cancer.
This trial tests an experimental personalized cancer vaccine (V940) combined with pembrolizumab and chemotherapy for people with advanced squamous non-small cell lung cancer that has spread. The goal is to see if adding the vaccine helps the immune system fight the cancer better.
This study tests a new personalized cancer vaccine (V940) plus Keytruda versus a placebo plus Keytruda for people with non-small cell lung cancer that was removed by surgery. The goal is to see if the vaccine helps prevent the cancer from coming back.
This trial tests whether giving a personalized cancer vaccine (Intismeran) with or without an immunotherapy drug (pembrolizumab) after lung cancer surgery can help prevent the cancer from coming back in patients with early-stage, high-risk non-small cell lung cancer.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a new drug (EIK1001) combined with the standard immunotherapy pembrolizumab (Keytruda) for people with advanced melanoma that cannot be removed by surgery or has spread. The goal is to see if adding EIK1001 is more effective than placebo plus pembrolizumab.
Hear when a new Malignant Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.